{"nctId":"NCT00454207","briefTitle":"Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension","startDateStruct":{"date":"2007-04"},"conditions":["Pulmonary Hypertension"],"count":44,"armGroups":[{"label":"sildenafil citrate (UK-92,480)","type":"EXPERIMENTAL","interventionNames":["Drug: sildenafil citrate (UK-92,480)"]}],"interventions":[{"name":"sildenafil citrate (UK-92,480)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects aged 16 and over, and classified as having pulmonary arterial hypertension\n* Subjects who meet the following conditions on right heart catheterization at screening or baseline: mean pulmonary arterial pressure of ≥ 25mmHg and pulmonary capillary wedge pressure of ≤ 15mmHg at rest\n* Subjects whose baseline 6-Minute Walk test distance is \\>100 m and \\<450 m\n\nExclusion Criteria:\n\n* Significant Hepatic and/or renal disorder\n* Subjects with known hereditary degenerative retinal disorders (such as retinitis pigmentosa) or history of non-arteritic ischemic optic neuropathy (NAION)\n* Subjects who are currently receiving nitrates or nitric oxide donors in any form, ritonavir, ketoconazole and itraconazole","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：6-minute walk distance at Week 12 minus 6-minute walk distance at baseline. The 6-minute walk distance:total distance walked during the 6-minute walk test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","spread":"74.9"}]}]}]},{"type":"PRIMARY","title":"Change in the Mean Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change:Mean pulmonary arterial pressure at Week 12 minus mean pulmonary arterial pressure at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"8.2"}]}]}]},{"type":"PRIMARY","title":"Change in the Pulmonary Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Pulmonary vascular resistance at Week 12 minus pulmonary vascular resistance at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-246.49","spread":"301.17"}]}]}]},{"type":"SECONDARY","title":"Change in the 6-minute Walk Distance From Baseline at Week 8 in Participants Who Entered the Study From Part I","description":"Change：6-minute walk distance at Week 8 minus 6-minute walk distance at baseline.\n\nThe 6-minute walk distance:Total distance walked during the 6- minute walk test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":"75.3"}]}]}]},{"type":"SECONDARY","title":"Change in the Systolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Systolic pulmonary arterial pressure at Week 12 minus Systolic pulmonary arterial pressure at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"13.4"}]}]}]},{"type":"SECONDARY","title":"Change in the Diastolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Diastolic pulmonary arterial pressure at Week 12 minus diastolic pulmonary arterial pressure at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"8.3"}]}]}]},{"type":"SECONDARY","title":"Change in the Systolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Systolic systemic blood pressure at Week 12 minus systolic systemic blood pressure at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"16.5"}]}]}]},{"type":"SECONDARY","title":"Change in the Diastolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Diastolic systemic blood pressure at Week 12 minus diastolic systemic blood pressure at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"9.0"}]}]}]},{"type":"SECONDARY","title":"Change in the Mean Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Mean systemic blood pressure:diastolic blood pressure+(systolic blood pressure-diastolic blood pressure)/3.\n\nChange：Mean systemic blood pressure at Week 12 minus mean systemic blood pressure at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"12.9"}]}]}]},{"type":"PRIMARY","title":"Change in the Cardiac Output From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Cardiac output at Week 12 minus cardiac output at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.556","spread":"1.000"}]}]}]},{"type":"SECONDARY","title":"Change in the Pulmonary Capillary Wedge Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Pulmonary capillary wedge pressure at Week 12 minus pulmonary capillary wedge pressure at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"3.14"}]}]}]},{"type":"SECONDARY","title":"Change in the Right Atrial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Right atrial pressure at Week 12 minus right atrial pressure at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"4.4"}]}]}]},{"type":"SECONDARY","title":"Change in the Cardiac Index From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Cardiac index at Week 12 minus cardiac index at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"0.62"}]}]}]},{"type":"SECONDARY","title":"Change in the Heart Rate From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Heart rate at Week 12 minus heart rate at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.14","spread":"7.45"}]}]}]},{"type":"SECONDARY","title":"Change in the Pulmonary Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change:Pulmonary vascular resistance index at Week 12 minus pulmonary vascular resistance index at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-382.00","spread":"491.80"}]}]}]},{"type":"SECONDARY","title":"Change in the Systemic Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Systemic vascular resistance at Week 12 minus systemic vascular resistance at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-265.77","spread":"785.52"}]}]}]},{"type":"SECONDARY","title":"Change in the Systemic Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Systemic vascular resistance index at Week 12 minus systemic vascular resistance index at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-409.89","spread":"1271.30"}]}]}]},{"type":"SECONDARY","title":"Change in the Mixed Venous Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Mixed venous oxygen saturation at Week 12 minus mixed venous oxygen saturation at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.91","spread":"9.05"}]}]}]},{"type":"SECONDARY","title":"Change in the Arterial Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Arterial oxygen saturation at Week 12 minus arterial oxygen saturation at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.440","spread":"5.437"}]}]}]},{"type":"SECONDARY","title":"Change in the Arterial Oxygen Partial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Arterial oxygen partial pressure at Week 12 minus arterial oxygen partial pressure at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.02","spread":"11.17"}]}]}]},{"type":"SECONDARY","title":"Change in the Partial Pressure of Mixed Venous Oxygen From Baseline at Week 12 in Participants Who Entered the Study From Part I","description":"Change：Partial pressure of mixed venous oxygen at Week 12 minus partial pressure of mixed venous oxygen at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"4.35"}]}]}]},{"type":"SECONDARY","title":"Changes in the World Health Organization (WHO) Functional Class of Pulmonary Arterial Hypertension From Baseline at Weeks 12 in Participants Who Entered the Study From Part I","description":"The cross-tabulation table on the WHO functional classes of pulmonary arterial hypertension at baseline and Week 12. The WHO functional classes of pulmonary arterial hypertension:Class I (pulmonary arterial hypertension patients with no limitation in physical activity) to Class IV (pulmonary arterial hypertension patients who can not perform a physical activity without any symptoms).","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in the BORG Dyspnoea Score From Baseline at Week 8 and Week 12 in Participants Who Entered the Study From Part I","description":"Change：BORG dyspnoea score at Week 8 and Week 12 minus BORG dyspnoea score at baseline. BORG dyspnoea score:Scale 0 (no breathlessness at all) to 10 (maximum). The score reflected the maximum degree of dyspnoea that the participants experienced at any time during the 6-minute walk distance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":"1.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":"1.94"}]}]}]},{"type":"SECONDARY","title":"Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 4, Week 8 and Week 12 in Participants Who Entered the Study From Part I","description":"Change：Plasma brain natriuretic peptide level at Week 4, Week 8 and Week 12 minus plasma brain natriuretic peptide level at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-78.00","spread":"166.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-88.25","spread":"178.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-61.82","spread":"209.96"}]}]}]},{"type":"SECONDARY","title":"Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II","description":"Change：6-minute walk distance at Week 12 minus 6-minute walk distance at baseline. The 6-minute walk distance:Total distance walked during the 6- minute walk test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.5","spread":"34.1"}]}]}]},{"type":"SECONDARY","title":"Change in the World Health Organization (WHO) Functional Class From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II","description":"The cross-tabulation table on the WHO functional classes of pulmonary arterial hypertension at baseline and Week 12. The WHO functional classes of pulmonary arterial hypertension:Class I (pulmonary arterial hypertension patients with no limitation in physical activity) to Class IV (pulmonary arterial hypertension patients who can not perform a physical activity without any symptoms).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in the BORG Dyspnoea Score From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II","description":"Change：BORG dyspnoea score at Week 12 minus BORG dyspnoea score at baseline. BORG dyspnoea score:Scale 0 (no breathlessness at all) to 10 (maximum). The score reflected the maximum degree of dyspnoea that the participants experienced at any time during the 6-minute walk distance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 12 in Participants Who Newly Enterd the Study From Part II","description":"Change：Plasma brain natriuretic peptide level at Week 12 minus plasma brain natriuretic peptide level at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.91","spread":"55.94"}]}]}]},{"type":"SECONDARY","title":"Maximum Plasma Concentrations (Cmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320","description":"Maximum plasma concentrations was calculated from the observed value of plasma concentrations in each participant","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"164.88","spread":"74.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.27","spread":"30.67"}]}]}]},{"type":"SECONDARY","title":"Time to First Occurrence of Maximum Plasma Concentrations (Tmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320","description":"Time to first occurrence of maximum plasma concentrations were calculated from the observed value of plasma concentrations in each participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.102","spread":"0.499"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.611","spread":"1.024"}]}]}]},{"type":"SECONDARY","title":"The Area Under the Curve (AUC) From Time 0 to Time 8 Hour of Sildenafil and Sildenafil's Metabolite, UK-103,320","description":"The area under the curve from time 0 to time 8 hour was calculated from area under the curve in each perticipant on the date of blood sampling using the linear/log trapezoidal rule","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"545.14","spread":"294.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"365.85","spread":"186.55"}]}]}]},{"type":"SECONDARY","title":"The Average Plasma Concentration (Css,av) of Sildenafil at Steady State","description":"The average plasma concentration of sildenafil at steady state was calculated from the area under the curve from time 0 to 8 hour/dosing interval (8 hours).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.14","spread":"36.86"}]}]}]},{"type":"SECONDARY","title":"The Average Plasma Trough Concentration (Ctrough) of Sildenafil","description":"The average plasma trough concentration of sildenafil was calculated from the observed value before administration of the drug in each participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.608","spread":"12.438"}]}]}]},{"type":"SECONDARY","title":"Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)","description":"The total number of participants with laboratory test abnormalities without regard to baseline abnormality.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":44},"commonTop":["Nasopharyngitis","Headache","Flushing","Pyrexia","Diarrhoea"]}}}